BR0309032A - Método para tratar sintomas vasomotores, a menopausa, deficiências hormonais em um paciente, e para tratar um paciente que sofre de sintomas vasomotores - Google Patents

Método para tratar sintomas vasomotores, a menopausa, deficiências hormonais em um paciente, e para tratar um paciente que sofre de sintomas vasomotores

Info

Publication number
BR0309032A
BR0309032A BR0309032-9A BR0309032A BR0309032A BR 0309032 A BR0309032 A BR 0309032A BR 0309032 A BR0309032 A BR 0309032A BR 0309032 A BR0309032 A BR 0309032A
Authority
BR
Brazil
Prior art keywords
vasomotor symptoms
treat
patient
menopause
patient suffering
Prior art date
Application number
BR0309032-9A
Other languages
English (en)
Inventor
Thomas W Leonard
R Forrest Waldon
Original Assignee
Barr Lab Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Barr Lab Inc filed Critical Barr Lab Inc
Publication of BR0309032A publication Critical patent/BR0309032A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

"MéTODO PARA TRATAR SINTOMAS VASOMOTORES, A MENOPAUSA, DEFICIêNCIAS HORMONAIS EM UM PACIENTE, E PARA TRATAR UM PACIENTE QUE SOFRE DE SINTOMAS VASOMOTORES". A presente invenção inclui métodos para tratar sintomas vasomotores através da administração de compostos estrogênicos. Os métodos apresentados podem incluir terapia de estrogênio de partida em uma dose alta e, depois diminuindo a dose assim que a terapia se mostrar eficaz.
BR0309032-9A 2002-04-03 2003-01-31 Método para tratar sintomas vasomotores, a menopausa, deficiências hormonais em um paciente, e para tratar um paciente que sofre de sintomas vasomotores BR0309032A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36990502P 2002-04-03 2002-04-03
PCT/US2003/002873 WO2003084547A1 (en) 2002-04-03 2003-01-31 Step-down estrogen therapy

Publications (1)

Publication Number Publication Date
BR0309032A true BR0309032A (pt) 2005-02-01

Family

ID=28792001

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0309032-9A BR0309032A (pt) 2002-04-03 2003-01-31 Método para tratar sintomas vasomotores, a menopausa, deficiências hormonais em um paciente, e para tratar um paciente que sofre de sintomas vasomotores

Country Status (7)

Country Link
US (1) US20030216366A1 (pt)
EP (1) EP1494679A4 (pt)
AU (1) AU2003210759B2 (pt)
BR (1) BR0309032A (pt)
CA (1) CA2481310A1 (pt)
MX (1) MXPA04009671A (pt)
WO (1) WO2003084547A1 (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ591627A (en) 2001-12-05 2012-09-28 Teva Womens Health Inc Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology
US7345096B2 (en) * 2002-10-15 2008-03-18 Wyeth Use of norepinephrine reuptake modulators for preventing and treating vasomotor symptoms
EP1624848A4 (en) * 2003-05-02 2009-02-25 Duramed Pharmaceuticals Inc METHOD FOR HORMONY TREATMENT WITH CONTRAZEPTVA SCHEMATES WITH EXTENDED CYCLE
NZ545130A (en) * 2003-07-16 2009-03-31 Duramed Pharmaceuticals Inc Methods of hormonal treatment utilizing contraceptive regimens with continuous estrogen administration
US20060040904A1 (en) * 2004-08-17 2006-02-23 Ahmed Salah U Vaginal cream compositions, kits thereof and methods of using thereof
US20070111975A1 (en) 2004-10-07 2007-05-17 Duramed Pharmaceuticals, Inc. Methods of Hormonal Treatment Utilizing Ascending-Dose Extended Cycle Regimens
MX2007004120A (es) * 2004-10-07 2007-06-15 Duramed Pharmaceuticals Inc Metodos de tratamiento hormonal utilizando regimentes de ciclo prolongado de dosis ascendente.
WO2007076144A2 (en) * 2005-12-27 2007-07-05 Duramed Pharmaceuticals, Inc. Conjugated estrogen compositions, applicators, kits, and methods of making and use thereof
US20080021003A1 (en) * 2006-06-13 2008-01-24 Vladimir Hanes Extended step-down estrogen regimen
US8617597B2 (en) 2006-07-06 2013-12-31 Bayer Intellectual Property Gmbh Pharmaceutical composition containing a tetrahydrofolic acid
EP2566877A4 (en) 2010-05-05 2013-10-09 Teva Womens Health Inc METHOD FOR REDUCING SYMPTOMS IN PATIENTS WITH INDIVIDUAL DOSAGE FORMS WITH STEP BY STEP RELEASE

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2271832A1 (en) * 1974-05-22 1975-12-19 Dynachim Sarl Compsns. contg. sex hormones and their esters - for improving wt. gain in meat animals
US4381298A (en) * 1981-10-13 1983-04-26 Coulson Patricia B Oral male contraceptive composition
US4826831A (en) * 1983-08-05 1989-05-02 Pre Jay Holdings Limited Method of hormonal treatment for menopausal or post-menopausal disorders involving continuous administration of progestogens and estrogens
US5108995A (en) * 1987-09-24 1992-04-28 Jencap Research Ltd. Hormone preparation and method
US5043331A (en) * 1989-06-15 1991-08-27 Orion-Yhtyma Oy Treatment of postmenopausal disorders
AU5855794A (en) * 1993-01-19 1994-08-15 Endorecherche Inc. Therapeutic uses and delivery systems of dehydroepiandrosterone
US6262115B1 (en) * 1995-05-22 2001-07-17 Alza Coporation Method for the management of incontinence
US5861431A (en) * 1995-06-07 1999-01-19 Iotek, Inc. Incontinence treatment
US6139873A (en) * 1996-07-10 2000-10-31 Cedars-Sinai Medical Center Combined pharmaceutical estrogen-androgen-progestin
ZA979204B (en) * 1996-10-16 1999-04-14 American Home Prod Use of 8,9-dehydroestrone in treating vasomotor symptoms
WO2000074684A1 (en) * 1999-06-04 2000-12-14 The General Hospital Corporation Pharmaceutical formulations for treating postmenopausal and perimenopausal women, and their use
TR200200406T2 (tr) * 1999-06-11 2002-06-21 Watson Pharmaceuticals, Inc. Kadınlara oral olmayan yollarla androjenik steroidlerin uygulanması
US20010034340A1 (en) * 2000-03-20 2001-10-25 American Home Products Corporation Hormone replacement therapy

Also Published As

Publication number Publication date
EP1494679A1 (en) 2005-01-12
AU2003210759A1 (en) 2003-10-20
US20030216366A1 (en) 2003-11-20
EP1494679A4 (en) 2009-10-28
CA2481310A1 (en) 2003-10-16
AU2003210759B2 (en) 2007-01-25
WO2003084547A1 (en) 2003-10-16
MXPA04009671A (es) 2005-01-25

Similar Documents

Publication Publication Date Title
BR0314308A (pt) Composto, composição farmacêutica, métodos para bloquear uma combinação de mu, kappa, delta ou receptor (heterodìmero) dos mesmos em mamìferos, para tratar ou prevenir obesidade e doenças relacionadas, para suprimir o apetite em um paciente em necessidade deste, e para realizar a perda de peso em um paciente obeso, e, uso de um composto
DE60129550D1 (de) Verwendung von niedrigen dosen estrogen in kombination mit immunotherapeutischen verbindungen zur behandlung von immunkrankheiten
AU2005202257C1 (en) Azacyclic compounds for use in the treatment of serotonin related diseases
AR043188A1 (es) Metodos y composiciones para el tratamiento de enfermedades y trastornos asociados con niveles elevados de citoquinas proinflamatorias
ZA200409388B (en) Methods and compositions using immunodulatory compounds for treatment and management of cancers and other diseases
TW200500355A (en) Methods and compositions using immunomodulatory compounds for treatment and management of cancers and other diseases
BR0116370A (pt) Composto, composição farmacêutica, uso de um composto, e, método de tratamento de uma doença ou condição mediada por hppar em um paciente.
BR0308928A (pt) Uso de toxina botulìnica para o tratamento de doenças cardiovasculares, bem como composição para uso em um procedimento cardiovascular
ATE355374T1 (de) Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen
BR0309032A (pt) Método para tratar sintomas vasomotores, a menopausa, deficiências hormonais em um paciente, e para tratar um paciente que sofre de sintomas vasomotores
ATE359068T1 (de) Methode zur behandlung der symptome hormoneller veränderungen, einschliesslich hitzewallungen
BR0316458A (pt) Composto, composição farmacêutica, método de tratamento ou prevenção de doenças, método para intensificar a cognição em um paciente saudável, e, uso de um composto
BR0316723A (pt) Derivados de anilinopirazol úteis para o tratamento de diabetes
BR0010515A (pt) Sistema terapêutico de ministração transdérmica, processo para mascarar um odor desagrádavel e uso de um óleo essencial em um sistema terapéutico de ministração transdérmica
CO5190664A1 (es) Terapia de combinacion para el tratamiento de migrana administracion de un receptor 5ht, cafeina y un inhibidor de ciclooxigenasa-2
BR0311146A (pt) Uso de tibolona e de modulador de receptor de estrogênio seletivo, e, método e kit para o tratamento de um sintoma relacionado com a deficiência de estrogênio em um paciente do sexo feminino
MXPA05010871A (es) Metodos para administrar estrogenos y progestinas.
EA199800864A1 (ru) Способ лечения при боли, вызванной мигренью
DK1237562T3 (da) Fremgangsmåde til fremstilling af mikania-ekstrakter, som indeholder mikanolid og dihydromikanolid, og anvendelse i behandlingen af prolifererende sygdomme
BR0314180A (pt) Aminoéteres substituìdos para o tratamento da doença de alzheimer
DK0986393T3 (da) Anvendelse af et nitroxid eller et prodrug heraf ved profylaktisk og terapeutisk behandling af cancer
BR0311613A (pt) Métodos para inibição, tratamento ou prevenção de sintomas de atrofia da pele, ou atrofia epitelial ou da mucosa nas mulheres e utilização de composto
SI1596879T1 (sl) Uporaba spojine kahalalida za pripravo zdravila za zdravljenje luskavice
WO2003032961A3 (en) Methods for preventing and treating bone loss with steroid compounds
BRPI0410657A (pt) composto, composição farmacêutica, uso de um composto, método para tratar um distúrbio de um paciente, e, processo para a preparação de um composto

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: PARA:INT.CI. A61K 31/56, A61P 5/00

Ipc: A61K 31/56 (2011.01), A61P 5/00 (2011.01)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07F Notification of approval that there is no relation to art. 229 of lpi (pipeline patents) [chapter 7.6 patent gazette]

Free format text: NOTIFICACAO DE NAO ANUENCIA RELACIONADA COM O ART. 229 DA LPI

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 12A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2291 DE 02/12/2014.